NM_004444.5(EPHB4):c.2405A>G (p.Asp802Gly) AND Capillary malformation-arteriovenous malformation 2

Clinical significance:Likely pathogenic (Last evaluated: Mar 29, 2019)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
2 submissions [Details]
Record status:

Allele description [Variation Report for NM_004444.5(EPHB4):c.2405A>G (p.Asp802Gly)]

NM_004444.5(EPHB4):c.2405A>G (p.Asp802Gly)

EPHB4:EPH receptor B4 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_004444.5(EPHB4):c.2405A>G (p.Asp802Gly)
  • NC_000007.14:g.100806499T>C
  • NG_052671.1:g.26023A>G
  • NM_004444.5:c.2405A>GMANE SELECT
  • NP_004435.3:p.Asp802Gly
  • NC_000007.13:g.100404121T>C
  • NM_004444.4:c.2405A>G
Protein change:
D802G; ASP802GLY
OMIM: 600011.0003; dbSNP: rs776410552
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_004444.5:c.2405A>G - missense variant - [Sequence Ontology: SO:0001583]


Capillary malformation-arteriovenous malformation 2 (CMAVM2)
MONDO: MONDO:0020785; MedGen: C4748670; OMIM: 618196

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000853237OMIMno assertion criteria providedPathogenic
(Nov 21, 2018)
germlineliterature only

PubMed (1)
[See all records that cite this PMID]

SCV000994943SIB Swiss Institute of Bioinformaticscriteria provided, single submitter
Likely pathogenic
(Mar 29, 2019)

PubMed (2)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownunknownnot providednot providednot providednot providednot providedcuration
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only



EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report.

Yu J, Streicher JL, Medne L, Krantz ID, Yan AC.

Pediatr Dermatol. 2017 Sep;34(5):e227-e230. doi: 10.1111/pde.13208. Epub 2017 Jul 21.

PubMed [citation]

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]

Details of each submission

From OMIM, SCV000853237.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (1)


In an 8-year-old white boy with multiple capillary malformations (CMAVM2; 618196), Yu et al. (2017) identified heterozygosity for a de novo c.2405A-G transition in the EPHB4 gene, resulting in an asp802-to-gly (D802G) substitution. His unaffected parents did not carry the mutation. The mutation was identified by whole-exome sequencing.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

From SIB Swiss Institute of Bioinformatics, SCV000994943.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (2)


This variant is interpreted as a Likely pathogenic for Capillary malformation-arteriovenous malformation 2. The following ACMG Tag(s) were applied: PM2-Supporting: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM1: Located in a mutational hot spot and/or critical and well-established functional domain (e.g.,active site of an enzyme) without benign variation. PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM6: Assumed de novo, but without confirmation of paternity and maternity.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 7, 2021

Support Center